

COVID-19: Medication therapies

COVID-19 therapies

Welia Health offers several medication therapies for individuals who have tested positive for COVID-19. Use of these medications is prioritized based on those who are most at risk of severe COVID-19 complications. A scoring system, called M-MASS scoring, is used to evaluate those most at risk.

At this time, when demand for COVID-19 medications is high and supply is limited, the Minnesota Department of Health follows an ethical framework for equitable distribution of these medications to patients throughout Minnesota.

Please note the following:

- You, or your insurance company, will be billed for a visit if you choose to receive any of the available COVID-19 medications.
- If you are pregnant and test positive for COVID-19, you should see your provider right away.

If you test positive for COVID-19, have calculated your M-MASS** score, and are eligible and interested in receiving COVID-19 medications, please call 320.679.1313 to speak to a Welia Health nurse.

You may also apply for monoclonal antibodies by using the MNRAP (Minnesota Resource Allocation Platform For COVID-19 Treatment) screening process which can be found at www.health.state.mn.us/diseases/coronavirus/mnrapppeople.html.

Sources:

Adapted with information from the Minnesota Department of Health:

- health.state.mn.us/diseases/coronavirus/meds.html
- health.state.mn.us/diseases/coronavirus/hcp/paxmovethical.pdf

COVID-19 vaccines

Medications to treat COVID-19 should not be used in place of vaccination. Welia Health strongly recommends you get vaccinated and boosted to help manage and limit the spread of COVID-19.

** M-MASS eligibility

Calculate your M-MASS score using the following scale.

Are you:

65 years or older	2 points	_____
Immunocompromised	4 points	_____
12 years or older and pregnant	4 points	_____

Do you have:

BMI of 35 (kg/m ²)	2 points	_____
Diabetes	2 points	_____
Chronic kidney disease	3 points	_____
Cardiovascular disease and are 55 years or older	2 points	_____
Chronic respiratory disease and are 55 years or older	2 points	_____
Hypertension (high blood pressure) and are 55 years or older	1 point	_____

Total points: _____

Refer the chart on the back for eligibility for each medication therapy.

Medication therapies for COVID-19

Name	Paxlovid	Molnupiravir	Sotrovimab
Type of medication	Antiviral	Antiviral	Monoclonal antibody
Authorized use(s)	Treatment of mild to moderate symptoms in high-risk patients with COVID-19 symptoms.	Treatment of mild to moderate symptoms in high-risk patients with COVID-19 symptoms.	Treatment of mild to moderate symptoms in high-risk patients with COVID-19 symptoms.
Age eligibility	Ages 12 years and older	Ages 18 years and older	Ages 12 years and older
Weight eligibility	88 pounds or more	88 pounds or more	88 pounds or more
Other criteria for treatment	<ul style="list-style-type: none"> • Test positive for SARS-CoV-2 • Be within 5 days of the start of symptoms • Not pregnant or breastfeeding* • Patient must not be hospitalized 	<ul style="list-style-type: none"> • Test positive for SARS-CoV-2 • Be within 5 days of the start of symptoms • Not pregnant or breastfeeding • Patient must not be hospitalized 	<ul style="list-style-type: none"> • Test positive for SARS-CoV-2 • Be within 7 days of the start of symptoms • Patient must not be hospitalized
Emergency Use Authorization (EUA)	The Food and Drug Administration has issued Emergency Use Authorizations for all listed therapies. They may not be appropriate for all individuals. Learn more by downloading and reviewing fact sheets using the links provided.		
EUA Fact Sheet (English)	<p>Fact Sheet for Patients And Caregivers</p> <p>Emergency Use Authorization (EUA) Of Paxlovid For Coronavirus Disease 2019 (COVID-19)</p> <p>fda.gov/media/155051/download</p>	<p>Fact Sheet for Patients And Caregivers</p> <p>Emergency Use Authorization (EUA) Of Molnupiravir For Coronavirus Disease 2019 (COVID-19)</p> <p>fda.gov/media/155055/download</p>	<p>Fact Sheet for Patients And Caregivers</p> <p>Emergency Use Authorization (EUA) Of Sotrovimab For Coronavirus Disease 2019 (COVID-19)</p> <p>gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Sotrovimab/pdf/SOTROVIMAB-PATIENT-FACT-SHEET.PDF</p>
EUA Fact Sheet (Spanish)	<p>Hoja de Datos para Pacientes y Cuidadores</p> <p>Autorización de Uso de Emergencia (EUA) de Paxlovid para la Enfermedad por el Coronavirus 2019 (COVID-19)</p> <p>fda.gov/media/155075/download</p>	<p>Hoja de Datos para Pacientes y Cuidadores</p> <p>Autorización de Uso de Emergencia (EUA) de Molnupiravir para la Enfermedad por el Coronavirus 2019 (COVID-19)</p> <p>fda.gov/media/155115/download</p>	<p>Hoja de Datos para Pacientes y Cuidadores</p> <p>Autorización de Uso de Emergencia (EUA) de Sotrovimab para la Enfermedad por el Coronavirus 2019 (COVID-19)</p> <p>https://www.sotrovimab.com/content/dam/cf-pharma/hcp-sotrovimab-phase2/en_US/sotrovimab-eua-fact-sheet-for-patients-in-spanish.pdf</p>
M-MASS score	2 or greater	Range between 1-3	0
MNRAP Screening	You may apply for monoclonal antibodies by using the MNRAP (Minnesota Resource Allocation Platform For COVID-19 Treatment) screening process which can be found at www.health.state.mn.us/diseases/coronavirus/mnrapppeople.html .		

* Pregnant women will require an informed consent visit with a physician or advanced practice provider.